RedHill’s P2/3 COVID-19 candidate Opaganib reduces ARDS-related blood clotting
Opaganib demonstrated reduced thrombosis in a preclinical model of ARDSCredit: RedHill Biopharma Acute respiratory distress syndrome (ARDS)-induced thrombosis (blood clotting) ...